Turbostart, a global venture capital platform, has invested $1 million in Ai Health Highway as part of its pre-Series A funds round.
The funding is part of a larger $1.5 million round that includes major Rainmatter co-investments from Zerodha, The Chennai Angels, BITS BioCyTiH Foundation and other angel investors.
The financial backing will help Ai Health Highway strengthen its presence in India and accelerate its regulatory approvals globally. In addition, it will allow the expansion of its artificial intelligence and machine learning (AI/ML) solutions in the cardiorespiratory field.
Ai Health Highway’s flagship product
Ai Health Highway’s flagship product, AiSteth, is India’s first AI-enabled stethoscope. This innovative tool is transforming the cardiac care landscape by helping healthcare professionals and even non-specialists interpret heart sounds for early detection of life-threatening conditions.
AiSteth leverages advanced artificial intelligence and signal processing to turn traditional stethoscopes into more sophisticated diagnostic tools. This allows healthcare providers to make more informed clinical decisions, potentially saving lives through early intervention.
Expand access to healthcare with AI
The AiSteth stethoscope easily integrates into existing medical workflows and offers high-quality heart sound data capture, analysis and sharing capabilities. It makes healthcare more accessible and affordable, especially in underserved communities.
As part of Ai Health Highway’s broader mission, the company aims to reduce global premature deaths caused by non-communicable diseases (NCDs), which are responsible for more than 41 million deaths each year. Its goal is to reduce these deaths by 30% by 2030, focusing on early detection and intervention.
Leadership Comments
Commenting on the investment, Venkat Raju, Founder and CEO of Turbostart, said: “We are delighted to support Ai Health Highway and its exceptional founding team, who bring together a powerful combination of medical expertise, business acumen and technological innovation. Their work goes beyond updating the stethoscope: they are reinventing screening tools to make healthcare more accessible in the modern era. Its smart stethoscope technology has the potential to bring quality screening to underserved communities, democratizing access to early detection. “We are excited to see how they will transform healthcare accessibility, creating a significant impact in an industry where change is not only welcome, but necessary.”
Dr. (Maj) Satish S Jeevannavar, Founder, Ai Health Highway, added: “We are delighted to announce Turbostart as the lead investor in our pre-Series A round, along with co-investors Rainmatter by Zerodha and the Foundation. BITS BioCyTiH. Our existing investors, Chennai Angels, along with other angel investors, have also participated in this round. We are delighted to collaborate with Turbostart on this vital mission to tackle NCDs. “The expertise of their seasoned professionals and Centers of Excellence will be invaluable as we navigate the complex global healthcare landscape.”
Disclaimer:
The information contained in this post is for general information purposes only. We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the post for any purpose.
We respect the intellectual property rights of content creators. If you are the owner of any material featured on our website and have concerns about its use, please contact us. We are committed to addressing any copyright issues promptly and will remove any material within 2 days of receiving a request from the rightful owner.